<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>A new class of sleep drugs draws Wall Street’s attention</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>A new class of sleep drugs draws Wall Street’s attention</h1>
  <ul>
<li>Takeda additionally said the median weekly rates of cataplexy decreased more than 80% for oveporexton-treated patients during its studies.</li>
<li>The exam has several rounds, with each lasting roughly 40 minutes.</li>
<li>The median number of days per week that patients experienced no cataplexy had also grown, from 0 to between 4 and 5.</li>
<li>This story was originally published on BioPharma Dive.</li>
<li>Johnson &amp; Johnson, for instance, hopes that by blocking orexin-2, its experimental medicine seltorexant can be used to combat insomnia in patients with major depression.</li>
<li>That protein, called orexin-2, helps regulate important body functions like appetite, arousal and wakefulness, which has in turn made it a promising target for drug companies.</li>
<li>The furthest along in this pursuit is Takeda Pharmaceutical with its drug oveporexton, which recently met the main and secondary goals of two late-stage clinical trials that focused on the most common, “Type 1” form of n</li>
</ul>
<p><a href="https://finance.yahoo.com/m/ce2a065f-143b-3c6c-bc14-02b2564fdae8/a-new-class-of-sleep-drugs.html">Source</a> · 2025-09-08T15:48:00+00:00</p>
</body>
</html>